News | EuroPCR | May 05, 2020

EuroPCR Cancels Annual Meeting Due to COVID-19

EuroPCR Cancels Annual Meeting Due to COVID-19. #SARScov2 #COVID19

May 5, 2020 — The large European interventional cardiology conference EuroPCR has been cancelled due to the contenting containment efforts for COVID-19 (SARS-CoV-2).

"The sanitary and legal environment, and in particular the decisions of the French government barring public gatherings for events exceeding 5,000 participants, have resulted in us cancelling the EuroPCR 2020 Course in Paris as a consequence of the COVID-19 outbreak," stated a letter sent out by EuroPCR today from the EuroPCR Course Directors Andreas Baumbach, Alberto Cremonesi, Jean Fajadet and William Wijns.

They said over the last two to three months, the Paris Course on Revascularization (PCR) mission of sharing knowledge, experience and practice has remained more actively relevant than ever with multiple educational resources freely available on PCRonline.

The organizers of the meeting said they will be working with the program committee to provide a full update on late-breaking trials and other essential educational content. Details of the dates and platform to be used will be announced in the coming weeks.

"We reiterate our heartfelt solidarity to all those affected by the coronavirus across the globe and extend our warmest wishes for good health to you and your patients, colleagues and loved ones," the course directors said in the statement. 

For additional information on the status of EuroPCR. 

 

Related Cardiology Conference Cancellations Due to COVID-19:

Cardiology Meetings Continue to be Cancelled or Go Virtual Due to COVID-19

SCCT Plans to Make 2020 Annual Meeting Virtual Due to COVID-19

ACC Cancels 2020 Conference Amid Coronavirus Concerns

Heart Rhythm Society Cancels 2020 Meeting Due to COVID-19

European Heart Rhythm Association Cancelled Due to Coronavirus

 

Related Content

Rates of burnout pre- and peak COVID-19 pandemic increased across all members of the cardiology care team and was particularly striking among cardiovascular team members, which researchers said may be because they were more likely at the bedside as patients were dying. Among all cardiovascular clinicians – cardiologists, physician assistants, nurse practitioners, nurses, pharmacists and imaging technologists – half provided direct care to patients with COVID-19. #COVID19 #ACCCOVID

Rates of burnout pre- and peak COVID-19 pandemic increased across all members of the cardiology care team and was particularly striking among cardiovascular team members, which researchers said may be because they were more likely at the bedside as patients were dying. Among all cardiovascular clinicians – cardiologists, physician assistants, nurse practitioners, nurses, pharmacists and imaging technologists – half provided direct care to patients with COVID-19, and yet one of five reported not having adequate personal protective equipment (PPE). Not surprisingly, the rate of burnout was higher in this group. Getty Images
 

News | Coronavirus (COVID-19) | June 07, 2021
June 7, 2021 — The COVID-19 pandemic has taken a significant toll on cardiovascular clinicians, many of whom provide
U.S. positive COVID test case data for 2020 through June 3, 2021, It shows four clear waves of spikes in U.S. COVID cases. Most of these appeared to be partly fueled by people gathering during the July 4, Halloween, Thanksgiving, Christmas, New Year's, Valentine's Day, and easter holidays. Source: John Hopkins University

U.S. positive COVID test case data for 2020 through June 3, 2021, It shows four clear waves of spikes in U.S. COVID cases. Most of these appeared to be partly fueled by people gathering during the July 4, Halloween, Thanksgiving, Christmas, New Year's, Valentine's Day, and easter holidays. Source: Johns Hopkins University

News | Coronavirus (COVID-19) | June 04, 2021 | By Dave Fornell, Editor
Vaccinations appear to to be helping reduce...
MRI scan of heart damaged by COVID, which can cause myocarditis, infarction and/or ischemia. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Image courtesy of European Heart Journal

MRI scan of heart damaged by COVID, which can cause myocarditis, infarction and/or ischemia. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Read more. Image courtesy of European Heart Journal

News | Coronavirus (COVID-19) | June 03, 2021
DAIC's sister radiology magazine Imaging Technology News (ITN) has created a photo gallery that sho
The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams. #ACC21 #ACC2021

The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams.

Feature | Coronavirus (COVID-19) | May 18, 2021
May 18, 2021 — Artificial intelligence (AI) derived heart measurements were able to predict...
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21. #ACC #ACC21 #ACC2021

Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21.

News | Coronavirus (COVID-19) | May 18, 2021
May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly re
According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — The Centers for Disease Control and Prevention (CDC) just
Estimates of excess deaths, defined as the number of persons who have died from all causes, above the expected number of deaths for a given place and time, can provide a comprehensive account of mortality likely related to the COVID-19 pandemic, including deaths that are both directly and indirectly associated with COVID-19

Getty Images

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — Estimates of excess deaths, defined as the number of persons who have died from all causes, above the
One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infarction (STEMI), according to the latest, comprehensive data from The North American COVID-19 Myocardial Infarction (NACMI) Registry. The data was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. The study showed there was an alarming one-in-three patients dying with STEMI and COVID, compared to 4-in-100 #SCAI2021

The key slide from the SCAI 2021 NACMI late-breaking presentation showing the very high adverse rates for COVID STEMI heart attack patients (red) as compared to pre-pandemic STEMI patient controls (green).

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
May 3, 2021 – One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infar
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 13, 2021 | By Dave Fornell, Editor
(This story was updated May 7, 2021 in the last subheaded section)